-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: AFM-24I is...
-
Product Insights
NewLymphoproliferative Disorders – Drugs In Development, 2024
Empower your strategies with our Lymphoproliferative Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or...
-
Product Insights
NewSalivary Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Salivary Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Salivary gland cancer refers to malignant tumors that develop in the tissues of the salivary glands, which produce saliva to aid in digestion and maintain oral health. These glands are located in various areas of the mouth and throat, including the parotid glands (the largest salivary glands), submandibular glands, sublingual glands, and numerous minor glands throughout the mouth. Salivary gland cancers...
-
Product Insights
NewLeiomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewHuman Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat....
-
Product Insights
NewAnaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024
Empower your strategies with our Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma, involving abnormal growth of immune cells called lymphocytes. ALCL can affect the lymph nodes, skin, and other organs, often presenting as swollen lymph nodes or skin lumps. Two main subtypes exist: one linked to a genetic mutation and the other associated with breast implants. Treatment...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewNasopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Nasopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose, an area called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking including hoarseness, recurrent ear infections, face pain or numbness, headache, hearing loss, and...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...